Actualités PR-160705_FR104_Option-Janssen_EN-final Home > OSE Immunotherapeutics : exercise of option within global license agreement with Janssen > PR-160705_FR104_Option-Janssen_EN-final 18 juillet 2016 PR-160705_FR104_Option-Janssen_EN-final